Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ARQT
ARQT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARQT News
Arcutis Biotherapeutics Advances ZORYVE in Pediatric Dermatology
1d ago
Yahoo Finance
Biotech IPOs Show Strong Performance in Q1 2026
Apr 08 2026
Newsfilter
Arcutis Biotherapeutics Executive Sells Shares
Apr 08 2026
Fool
Arcutis Biotherapeutics Director Sells Shares
Apr 08 2026
NASDAQ.COM
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Globenewswire
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Newsfilter
Biotech Landscape Update: Regulatory Approvals and Acquisitions
Apr 03 2026
NASDAQ.COM
Arcutis Reports Positive Phase 2 Data for ZORYVE in Infants
Mar 30 2026
NASDAQ.COM
ZORYVE® Cream Shows Positive Results in Infant Eczema Treatment
Mar 28 2026
Newsfilter
Baron Health Care Fund Reports Strong Q4 2025 Performance
Mar 06 2026
seekingalpha
Arcutis to Present at TD Cowen Health Care Conference in Boston
Feb 27 2026
Yahoo Finance
Arcutis (ARQT) Q4 2025 Earnings Call Transcript
Feb 26 2026
NASDAQ.COM
Arcutis Biotherapeutics Q4 Earnings Exceed Expectations
Feb 25 2026
seekingalpha
Max Homa Shares Journey with Seborrheic Dermatitis
Feb 24 2026
Newsfilter
Arcutis and Take-Two Options Trading Activity Surges
Feb 19 2026
NASDAQ.COM
Tejara Capital Fully Exits Arcutis Biotherapeutics Stake
Feb 06 2026
Fool
Show More News
